地奥心血康联合西药治疗高血压合并冠状动脉性心脏病介入术后心绞痛的疗效

Study on Efficacy of Di’ao Xinxuekang Combined with Western Medicine in the Treatment of Hypertension with Angina Pectoris after Percutaneous Coronary Intervention

目的探讨地奥心血康联合西药治疗高血压合并冠状动脉性心脏病(简称冠心病)介入术后心绞痛的疗效。方法回顾性分析2018年1月至2020年8月收治的高血压合并冠心病介入术后心绞痛患者86例。对照组41例患者予以阿司匹林+阿托伐他汀+氯吡格雷治疗,观察组45例患者在此基础上加用地奥心血康软胶囊。比较两组患者临床疗效,观察治疗前及治疗3个月后血管内皮功能[一氧化氮(NO)、内皮素(ET)水平]、血清脂质过氧化物[超氧化物歧化酶(SOD)、丙二醛(MDA)]及炎症因子[同型半胱氨酸(Hcy)、生长分化因子-15(GDF-15)、可溶性细胞间黏附分子-1(sICAM-1)]水平、生活质量[西雅图心绞痛量表(SAQ)]变化情况。结果观察组患者治疗总有效率高于对照组患者,且差异有统计学意义(P<0.05);治疗3个月后,两组患者血清NO、SOD水平均较治疗前升高,且观察组患者高于对照组患者,血清ET、MDA、Hcy、GDF-15、sICAM-1水平均较治疗前降低,且观察组患者低于对照组患者,且差异均有统计学意义(P均<0.05);治疗3个月后,两组患者SAQ量表各维度评分均较治疗前升高,且观察组患者高于对照组患者,且差异均有统计学意义(P均<0.05)。结论地奥心血康联合西药治疗高血压合并冠心病介入术后心绞痛疗效确切,可缓解临床症状,改善血管内皮功能,降低血清脂质过氧化物和炎症因子水平,有利于患者生活质量的提高。

Objective To investigate the efficacy of Di’ao Xinxuekang soft capsule combined with conventional Western Medicine in the treatment of hypertension with angina pectoris after percutaneous coronary intervention.Methods Patients with hypertension complicated with angina pectoris after percutaneous coronary intervention were selected between January 2018 and August 2020,and their data were retrospectively analyzed.According to the different treatment plans,the patients were divided into control group and observation group.Patients in control group were treated with aspirin+atorvastatin+clopidogrel,and patients in observation group were additionally treated with Di’ao Xinxuekang soft capsule on this basis.After excluding confounding factors such as gender,age,complications,angina pectoris type,coronary artery disease type and medication status by propensity matching score method,thus 45 cases in observation group and 41 cases in control group were finally obtained.The clinical efficacy of the two groups was compared,and the vascular endothelial function[nitric oxide(NO),endothelin(ET)],lipid peroxides[superoxide dismutase(SOD),malondialdehyde(MDA)],inflammatory factors[homocysteine(Hcy),growth differentiation factor-15(GDF-15),soluble intercellular adhesion molecule-1(sICAM-1)]and quality of life[Seattle Angina Questionnaire(SAQ)]were observed before and three months after treatment.Results There were no significant differences in baseline data between the two groups(P>0.05).The total effective rate of treatment in observation group was higher than that in control group(P<0.05).After 3 months of treatment,the levels of serum NO and SOD of the two groups were higher than those before treatment,and the levels of observation group were higher than those of control group(P<0.05),and the levels of serum ET,MDA,Hcy,GDF-15 and sICAM-1 were lower than those before treatment,and the levels of observation group were lower than those of control group(P<0.05).After 3 months of treatment,the scores of dimensions of SAQ scale were higher than those before treatment,and the scores of observation group were higher than those of control group(P<0.05).Conclusion Di’ao Xinxuekang soft capsule combined with conventional Western Medicine has an exact efficacy in treating hypertension with angina pectoris after percutaneous coronary intervention.It can relieve clinical symptoms,improve vascular endothelial function,and reduce the levels of lipid peroxides and inflammatory factors,and it is beneficial to the improvement of quality of life.